Abstract
More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Current Pharmaceutical Design
Title: Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors
Volume: 15 Issue: 6
Author(s): Zhili Liu, Jing Zhang and Ao Zhang
Affiliation:
Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target
Abstract: More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.
Export Options
About this article
Cite this article as:
Liu Zhili, Zhang Jing and Zhang Ao, Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315639
DOI https://dx.doi.org/10.2174/138161209787315639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Current Concepts for Optimizing the Therapeutic Index of Glucocorticoid Receptor Ligands for Oral and Inhalative Use: Basic Considerations and Clinical Reality
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Homology Modeling of Human Nicotinamide/Nicotinic Acid Mononucleotide Adenylyltransferase 2: Insights into Isoenzyme-Specific Differences Using Molecular Docking Simulatons
Letters in Drug Design & Discovery Withdrawn: Alkaloidal Content, Medicinal, Properties of Peganum harmala L. (P. harmala)
Current Traditional Medicine Cytosine Methyltransferases as Tumor Markers
Current Genomics Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design ApoE ε4 Allele Related Alterations in Hippocampal Connectivity in Early Alzheimer’s Disease Support Memory Performance
Current Alzheimer Research Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MicroRNAs: Association with Radioresistant and Potential Uses of Natural Remedies as Green Gene Therapeutic Approaches
Current Gene Therapy Antiviral Sensing in Teleost Fish
Current Pharmaceutical Design Oncogenomics
Current Drug Metabolism Meet Our Editorial Board Member
Current Neuropharmacology Commentary Research Highlights (Amyloid β-Peptide and Alzheimer’s Disease: It’s All the RAGE)
CNS & Neurological Disorders - Drug Targets How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Exploring 1,3,4-Oxadiazole Scaffold for Anti-inflammatory and Analgesic Activities: A Review of Literature From 2005-2016
Mini-Reviews in Medicinal Chemistry Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Current Pharmaceutical Design Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design